SEC Form 4 · accession 0001209191-18-032716
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — President & CEO · Director
Period of report
May 21, 2018
Accepted (ET)
May 23, 2018 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 21, 2018 | M | 13,600 | $0.78 | A | 13,600 | D | |
| Common StockF2 | May 21, 2018 | S | 13,600 | $38.08 | D | 0 | D | |
| Common Stock | May 21, 2018 | M | 6,700 | $0.78 | A | 6,700 | D | |
| Common StockF3 | May 21, 2018 | S | 6,700 | $38.30 | D | 0 | D | |
| Common StockF4 | holding | — | — | — | 171,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $0.78 | May 21, 2018 | M | 20,300 | D | — | Sep 25, 2023 | Common Stock | 20,300 | 178,750 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. The lowest price at which shares were sold was $37.22 and the highest price at which shares were sold was $38.21. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- F3Represents the weighted average sale price. The lowest price at which shares were sold was $38.23 and the highest price at which shares were sold was $38.44.
- F4The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F5The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.